Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients

Bibliography

• JOHNSON M, KLEINBERG M, DANZIGER L, OSTROSKY-ZEICHNER L: Pharmacoeconomics of antifungal pharmacotherapy-challenges and future directions. Expert. Opin. Pharmacother. (2005) 6(15):2617-2632.
   PubMed Web of Science ®Google Scholar
• DIXON S, MCKEEN E, TABBERER M, PAISLEY S: Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. Pharmacoeconomics (2004) 22(7):421-433.
   PubMed Web of Science ®Google Scholar
• MARTINO R: Efficacy, safety and cost-effectiveness of amphotericin B lipid complex (ABLC): a review of the literature. Curr. Med. Res. Opin. (2004) 20(4):485-504.
   PubMed Web of Science ®Google Scholar
• BENNETT JE, POWERS J, WALSH T et al.: Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin. Infect. Dis. (2003) 36(Suppl. 3):S117-S122.
   PubMed Web of Science ®Google Scholar
• WILSON LS, REYES CM, STOLPMAN M et al.: The direct cost and incidence of systemic fungal infections. Value. Health (2002) 5(1):26-34.
   PubMed Web of Science ®Google Scholar
• MAERTENS J, BOOGAERTS M: The place for itraconazole in treatment. J. Antimicrob. Chemother. (2005) 56(Suppl. 1):i33-i38.
   PubMed Web of Science ®Google Scholar
• O’CONNELL B, CRAIG JI, MARCUS RE, LUDLAM H: Cost-effective use of liposomal amphotericin B. Clin. Lab. Haematol. (2002) 24(5):317-319.
   PubMedGoogle Scholar
• BURKIEWICZ JS, KOSTIUK KA, JACOBS RA, GUGLIELMO BJ: Impact of an intravenous fluconazole restriction policy on patient outcomes. Ann. Pharmacother. (2001) 35(1):9-13.
   PubMed Web of Science ®Google Scholar
• COLLINS CD, DE PESTEL DD, STUNTEBECK ER, SHEHAB N, ERBA HP, STEVENSON JG: Cost analysis of a febrile neutropenia algorithm with respect to empirical antifungal therapy in adult hematology/oncology patients. Value in Health (2005) 8(3):426-432. (Abstract).
   Google Scholar
• VAN BURIK JA, RATANATHARATHORN V, STEPAN DE et al.: Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. (2004) 39(10):1407-1416.
   PubMed Web of Science ®Google Scholar
• ULLMANN AJ, CORNELY OA, BURCHARDT A et al.: Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. (2006) 50(2):658-666.
   PubMed Web of Science ®Google Scholar
• GOODMAN JL, WINSTON DJ, GREENFIELD RA et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J Med. (1992) 326(13):845-851.
   PubMed Web of Science ®Google Scholar
• SLAVIN MA, OSBORNE B, ADAMS R et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation – a prospective, randomized, double-blind study. J. Infect. Dis. (1995) 171(6):1545-1552.
   PubMed Web of Science ®Google Scholar
• MARR KA, SEIDEL K, SLAVIN MA et al.: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood (2000) 96(6):2055-2061.
   PubMed Web of Science ®Google Scholar
• WINSTON DJ, CHANDRASEKAR PH, LAZARUS HM et al.: Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann. Intern. Med. (1993) 118(7):495-503.
   PubMed Web of Science ®Google Scholar
• ROTSTEIN C, BOW EJ, LAVERDIERE M et al.: Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin. Infect. Dis. (1999) 28(2):331-340.
   PubMed Web of Science ®Google Scholar
• MENICHETTI F, DEL FAVERO A, MARTINO P et al.: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell’ Adulto. Clin. Infect. Dis. (1999) 28(2):250-255.
   PubMed Web of Science ®Google Scholar
• LEATHER HL, WINGARD JR: Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom? Curr. Opin. Infect. Dis. (2002) 15(4):369-375.
   Google Scholar
• CENTRES FOR DISEASE CONTROL AND PREVENTION: Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR (2000) 2000(RR 10):22-24.
   Google Scholar
• KRUGER WH, BOHLIUS J, CORNELY OA et al.: Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the infectious diseases working party (AGIHO) of the german society of haematology and oncology. Ann. Oncol. (2005) 16(8):1381-1390.
   PubMed Web of Science ®Google Scholar
• KLASTERSKY J: Empirical antifungal therapy. Int. J. Antimicrob. Agents (2004) 23(2):105-112.
   PubMed Web of Science ®Google Scholar
• MORRISON VA: Echinocandin antifungals: review and update. Expert. Rev. Anti. Infect. Ther. (2006) 4(2):325-342.
   PubMedGoogle Scholar
• HARBARTH S, PESTOTNIK SL, LLOYD JF, BURKE JP, SAMORE MH: The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am. J. Med. (2001) 111(7):528-534.
   PubMed Web of Science ®Google Scholar
• ‘T WOUT JW, KUIJPER EJ, VERWEIJ PE, KULLBERG BJ: [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin]. Ned. Tijdschr. Geneeskd. (2004) 148(34):1679-1684.
   Google Scholar
• WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N. Engl. J. Med. (1999) 340(10):764-771.
   PubMed Web of Science ®Google Scholar
• JOHANSEN HK, GOTZSCHE PC: Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Cochrane. Database. Syst. Rev. (2000) 3:CD000969.
   Google Scholar
• CAGNONI PJ, WALSH TJ, PRENDERGAST MM et al.: Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Clin. Oncol. (2000) 18(12):2476-2483.
   PubMed Web of Science ®Google Scholar
• MOEREMANS K, ANNEMANS L, VANDOROS C, LIAROPOULOS L: Economic evaluation of intravenous itraconazole in presumed systemic fungal infection in neutropenic patients in Greece. Value in Health (2004) 7(6):811-817 (Abstract).
   Google Scholar
• WINGARD JR, WOOD CA, SULLIVAN E et al.: Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin. Ther. (2005) 27(6):960-969.
   PubMed Web of Science ®Google Scholar
• JOHANSEN HK, GOTZSCHE PC: Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane. Database. Syst. Rev. (2002) 2:CD000239.
   Google Scholar
• SCHNEEMANN M, BACHLI EB: Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections? Clin. Infect. Dis. (2004) 38(2):303-304.
   Google Scholar
• PELEG AY, WOODS ML: Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J. Antimicrob. Chemother. (2004) 54(4):803-808.
   PubMed Web of Science ®Google Scholar
• IMHOF A, WALTER RB, SCHAFFNER A: Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin. Infect. Dis. (2003) 36(8):943-951.
   PubMed Web of Science ®Google Scholar
• HARBARTH S, BURKE JP, LLOYD JF et al.: Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin. Infect. Dis. (2002) 35(12):e120-e127.
   PubMed Web of Science ®Google Scholar
• GREENBERG RN, CAGNONI PJ, WINGARD JR, PRENDERGAST MM, TONG KB: Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy. J. Medical Econ. (2002) 5:109-118.
   Google Scholar
• PRENDERGRAST MM, TONG KB: Amphotericin B-related nephrotoxicity has an economic impact on hospitals and health systems. Clin. Infect. Dis. (2003) 37(10):1396-1397.
   PubMedGoogle Scholar
• ERIKSSON U, SEIFERT B, SCHAFFNER A: Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br. Med. J. (2001) 322(7286):579-582.
   PubMed Web of Science ®Google Scholar
• SCHULENBURG A, SPERR W, RABITSCH W, KNOBL P, THALHAMMER F: Brief report: practicability and safety of amphotericin B deoxycholate as continuous infusion in neutropenic patients with hematological malignancies. Leuk. Lymphoma (2005) 46(8):1163-1167.
   PubMed Web of Science ®Google Scholar
• WALSH T, DONOWITZ G, DEPAUW B: Caspofungin versus liposomal amph otericin B for empirical therapy. N. Engl. J Med. (2005) 352(4):413-414.
   Google Scholar
• BOOGAERTS M, WINSTON DJ, BOW EJ et al.: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann. Intern. Med. (2001) 135(6):412-422.
   PubMed Web of Science ®Google Scholar
• MOEREMANS K, ANNEMANS L, JI-SO R, KANG-WON C, WAN-SHIK S: Economic evaluation of intravenous itrzaconazole in presumed systemic fungal infections in neutropenic patients in Korea. Value in Health (2005) 8(3):426-432 (Abstract).
   Google Scholar
• WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N. Engl. J. Med. (2002) 346(4):225-234.
   PubMed Web of Science ®Google Scholar
• PEARSON MM, ROGERS PD, CLEARY JD, CHAPMAN SW: Voriconazole: a new triazole antifungal agent. Ann. Pharmacother. (2003) 37(3):420-432.
   PubMed Web of Science ®Google Scholar
• STURKENBOOM MC, GOETTSCH WG, PICELLI G, HERINGS RM: Frequency of potential drug-drug interactions with triazole antifungal use in Dutch hospital settings. Value in Health (2004) 7(6): 811-817 (Abstract).
   Google Scholar
• WONG-BERINGER A, KRIENGKAUYKIAT J: Systemic antifungal therapy: new options, new challenges. Pharmacotherapy (2003) 23(11):1441-1462.
   PubMedGoogle Scholar
• DATRY A, BART-DELABESSE E: Caspofungin: mode of action and therapeutic applications. La revue de médecine interne (2005) Epub ahead of print.
   Google Scholar
• WALSH TJ, TEPPLER H, DONOWITZ GR et al.: Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J Med. (2004) 351(14):1391-1402.
   PubMed Web of Science ®Google Scholar
• WINGARD JR, LEATHER HL, WALSH TJ et al.: Pharmacoeconomic analysis comparing caspofungin to liposomal amphotericin B for empirical therapy for persistently febrile neutropenic patients. Program and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA – October 30 - November 2 (2004):0-1619.
   Google Scholar
• PAPPAS PG, REX JH, SOBEL JD et al.: Guidelines for treatment of candidiasis. Clin. Infect. Dis. (2004) 38(2):161-189.
   PubMed Web of Science ®Google Scholar
• KRAUSE DS, REINHARDT J, VAZQUEZ JA et al.: Phase II, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. (2004) 48(6):2021-2024.
   PubMed Web of Science ®Google Scholar
• OSTROSKY-ZEICHNER L, KONTOYIANNIS D, RAFFALLI J et al.: International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. (2005) 24(10):654-661.
   PubMed Web of Science ®Google Scholar
• MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347(25):2020-2029.
   PubMed Web of Science ®Google Scholar
• BETTS R, GLASMACHER A, MAERTENS J et al.: Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer (2006) 106(2):466-473.
   PubMed Web of Science ®Google Scholar
• PACHL J, SVOBODA P, JACOBS F et al.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. (2006) 42(10):1404-1413.
   PubMed Web of Science ®Google Scholar
• HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J Med. (2002) 347(6):408-415.
   PubMed Web of Science ®Google Scholar
• LEWIS JS, BOUCHER HW, LUBOWSKI TJ et al.: Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacotherapy (2005) 25(6):839-846.
   PubMed Web of Science ®Google Scholar
• WENZEL R, DEL FAVERO A, KIBBLER C et al.: Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. J. Antimicrob. Chemother. (2005) 55(3):352-361.
   PubMed Web of Science ®Google Scholar
• MARBAIX S, MARCINIAK A, DE MEES V, AOUN M: Cost effectiveness of voriconazole compared with conventional amphotericin B in first line treatment of invasive aspergillosis in Belgium. Value in Health (2003) 6(6):821-829 (Abstract).
   Google Scholar
• JANSEN JP, MEIS JF, BLIJLEVENS NM, VAN’T WOUT JW: Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr. Med. Res. Opin. (2005) 21(10):1535-1546.
   PubMed Web of Science ®Google Scholar
• MESROBIAN X, LOFTUS J, ROBERTS C, JANSEN J: Cost-effectiveness of voriconazole versus liposomal amphotericin B for invasive aspergillosis infection in the UK. Value in Health (2005) 8(6):A228-A236 (Abstract).
   Google Scholar
• JANSEN J, KERN W, RESCH A: Economic evaluation of voriconazole in the treatment of invasive aspergillosis in Germany. Value in Health (2004) 7(6):811-817 (Abstract).
   Google Scholar
• DERESINSKI SC, STEVENS DA: Caspofungin. Clin. Infect. Dis. (2003) 36(11):1445-1457.
   PubMed Web of Science ®Google Scholar